{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:21:56Z","timestamp":1792142516346,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,6]]},"abstract":"\n Aims<\/jats:title>\n \n To compare the safety and efficacy of a simpler titration algorithm for insulin degludec\/liraglutide (\n IDegLira<\/jats:styled-content>\n ) with that used in previous\n DUAL<\/jats:styled-content>\n trials in insulin\u2010na\u00efve patients with type 2 diabetes.\n <\/jats:p>\n <\/jats:sec>\n \n Research design and methods<\/jats:title>\n \n This 32\u2010week, open\u2010label, non\u2010inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin\u2009\u00b1\u2009pioglitazone to receive\n IDegLira<\/jats:styled-content>\n , titrated either once weekly, based on the mean of 2 pre\u2010breakfast plasma glucose (\n PG<\/jats:styled-content>\n ) readings (n\u2009=\u2009210), or twice weekly, based on the mean of 3 pre\u2010breakfast\n PG<\/jats:styled-content>\n readings (n\u2009=\u2009210).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Mean\n HbA1c<\/jats:styled-content>\n decreased from 8.2% (65\u2009mmol\/mol) to 6.1% (43\u2009mmol\/mol) with once\u2010weekly titration and from 8.1% (65\u2009mmol\/mol) to 6.0% (42\u2009mmol\/mol) with twice\u2010weekly titration; non\u2010inferiority was confirmed (estimated treatment difference: 0.12% [\u22120.04; 0.28]\n 95%<\/jats:sub>\n \n CI<\/jats:sub>\n <\/jats:styled-content>\n , 1.30\u2009mmol\/mol [\u22120.41; 3.01]\n 95%<\/jats:sub>\n \n CI<\/jats:sub>\n <\/jats:styled-content>\n ). Approximately 90% of patients achieved\n HbA1c<\/jats:styled-content>\n \u2009<\u20097% in each arm. Mean fasting\n PG<\/jats:styled-content>\n was similar after 32\u2009weeks. Weight change was \u22121.0\u2009kg vs \u22122.0\u2009kg for once\u2010weekly vs twice\u2010weekly titration. Rates of severe or blood glucose\u2010confirmed symptomatic hypoglycaemia were low in both arms: 0.16 events\/patient\u2010year of exposure (\n PYE<\/jats:styled-content>\n ) for once\u2010weekly, 0.76 events\/\n PYE<\/jats:styled-content>\n for twice\u2010weekly titration. Mean\n IDegLira<\/jats:styled-content>\n dose at 32\u2009weeks was 41 dose steps (41\u2009\n U IDeg<\/jats:styled-content>\n \/1.48\u2009mg\n L<\/jats:styled-content>\n ira) for both arms. Overall adverse event rates were 207.8 and 241.3 events\/100\n PYE<\/jats:styled-content>\n with once\u2010weekly and twice\u2010weekly titration, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n A pragmatic titration algorithm with once\u2010weekly adjustments based on 2\n PG<\/jats:styled-content>\n readings resulted in a safety and glycaemic efficacy profile similar to that with twice\u2010weekly adjustments based on 3 preceding\n PG<\/jats:styled-content>\n values in insulin\u2010na\u00efve patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12892","type":"journal-article","created":{"date-parts":[[2017,1,26]],"date-time":"2017-01-26T07:46:39Z","timestamp":1485416799000},"page":"858-865","source":"Crossref","is-referenced-by-count":64,"title":["Safety and efficacy of\n IDegLira<\/scp>\n titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs:\n DUAL VI<\/scp>\n randomized clinical trial"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-6551","authenticated-orcid":false,"given":"Stewart B.","family":"Harris","sequence":"first","affiliation":[{"name":"Schulich School of Medicine & Dentistry London Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u0151z\u0151","family":"Kocsis","sequence":"additional","affiliation":[{"name":"P\u00e9terfy Hospital and Emergency Center Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Prager","sequence":"additional","affiliation":[{"name":"Hietzing Hospital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Ridge","sequence":"additional","affiliation":[{"name":"American Health Network Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keval","family":"Chandarana","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Halladin","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.6.540"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.15277\/bjdvd.2015.019"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02176.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.11.2673"},{"key":"e_1_2_6_7_1","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini SD","year":"2009","journal-title":"Am. J. Manag. Care"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.11.007"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1355"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61335-0"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12498"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0448-0"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","unstructured":"Rosenstock J Aronson R Grunberger G et al. Benefits of LixiLan a titratable fixed\u2010ratio combination of insulin glargine plus lixisenatide versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan\u2010O Randomized Trial.Diabetes Care. 2016;39:2026\u20132035.","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.6.1282"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01881.x"},{"key":"e_1_2_6_22_1","unstructured":"World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Last amended by the 64th WMA Assembly; October 2013; Fortaleza Brazil."},{"key":"e_1_2_6_23_1","unstructured":"International Conference on Harmonisation.ICH harmonised tripartite guideline. Good Clinical Practice. 10 June1996."},{"key":"e_1_2_6_24_1","unstructured":"FDA Guidance.http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm071624.pdf. Accessed April 4 2016."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0051-1"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/11208110-000000000-00000"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12080"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2011"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2035"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:51:53Z","timestamp":1761886313000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/dom.12892"],"URL":"https:\/\/doi.org\/10.1111\/dom.12892","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}